EUVIMEDEUVIMED entdecken
Crossref

Targeting circSFPQ_008/SFPQ/BRCA1 axis for overcoming platinum resistance in ovarian cancer

Yinan Jiang, Dongmei Zhou, Yan Liu, Baixue Li, Renci Liu, Jianqi Li, Xiujie Sheng

MedScience · 2026-04 · 20 (2) · 329-344

DOI: 10.1007/s11684-026-1201-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedScience, online erschienen am 31.03.2026. Verfasst von Yinan Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Department of Gynecologic Oncology Research Office, Guangzhou Key Laboratory of Targeted Therapy for Gynecol…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, BRCA1 Protein, PTB-Associated Splicing Factor. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum resistance is the main cause of treatment failure in ovarian cancer. BRCA1/2-mediated DNA damage repairment is an important factor contributing to platinum resistance in ovarian cancer. Altering the expression levels of BRCA1/2 will affect the platinum sensitivity of ovarian cancer. We used proteomics to screen out SFPQ, which bound to BRCA1 with a high abundance. However, the role and potential mechanism of SFPQ in the progression of ovarian cancer remain unclear. Through immunohistochemical staining, we found that SFPQ was overexpressed in ovarian cancer tissues and associated with poor prognosis of patients. Functional analysis showed that SFPQ binds to BRCA1 and inhibits its ubiquitination and degradation, increases the expression level of BRCA1, and promotes platinum resistance of ovarian cancer. Exploration of the upstream mechanism revealed that hsa_circSFPQ_008, which was derived from the SFPQ parental gene, recruits HDAC1 to modify H3K27Ac of the SFPQ promoter and regulates its expression. This study reveals a novel regulatory mechanism by which SFPQ is involved in platinum resistance of ovarian cancer, providing a new theoretical basis for the individualized and precise treatment of ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsDrug Resistance, NeoplasmBRCA1 ProteinPTB-Associated Splicing FactorHumansFemaleCell Line, TumorHistone Deacetylase 1Gene Expression Regulation, NeoplasticAntineoplastic Agents

Stichwörter der Autor:innen

DNA damage repairSFPQovarian cancerplatinum resistance

Substanzen

BRCA1 ProteinBRCA1 protein, humanPTB-Associated Splicing FactorHistone Deacetylase 1HDAC1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Department of Gynecologic Oncology Research Office, Guangzhou Key Laboratory of Targeted Therapy for Gynecologic Oncology, The Third Affiliated Hospital, Guangzhou Medical Univer…
  • Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory…

Zitieren

APA

Jiang, Y., Zhou, D., Liu, Y., Li, B., Liu, R., Li, J., & Sheng, X. (2026). Targeting circSFPQ_008/SFPQ/BRCA1 axis for overcoming platinum resistance in ovarian cancer. MedScience, 20(2), 329-344. https://doi.org/10.1007/s11684-026-1201-7

Vancouver

Jiang Y, Zhou D, Liu Y, Li B, Liu R, Li J, et al. Targeting circSFPQ_008/SFPQ/BRCA1 axis for overcoming platinum resistance in ovarian cancer. MedScience. 2026;20(2):329-344. doi:10.1007/s11684-026-1201-7

BibTeX
@article{Jiang2026,
  author = {Jiang, Yinan and Zhou, Dongmei and Liu, Yan and Li, Baixue and Liu, Renci and Li, Jianqi and Sheng, Xiujie},
  title = {Targeting circSFPQ_008/SFPQ/BRCA1 axis for overcoming platinum resistance in ovarian cancer},
  journal = {MedScience},
  year = {2026},
  volume = {20},
  number = {2},
  pages = {329--344},
  doi = {10.1007/s11684-026-1201-7}
}
Kostenlos starten →